VERA · Vera Therapeutics, Inc.

Vera Therapeutics reported significantly widened Q1 2026 losses of $121.0 million, up from $51.7 million in the prior year quarter, primarily driven by a near-doubling of research and development expenses to $86.0 million from $41.3 million, reflecting intensified clinical and pre-commercial activities for atacicept in IgAN. General and administrative costs also more than doubled to $39.1 million from $15.9 million, likely tied to commercial infrastructure buildout including sales, marketing, market access, and compliance preparations ahead of a potential mid-2026 U.S. launch. CEO Marshall Fordyce emphasized execution focus on pre-commercial activities to support a successful launch pending FDA approval. The company bolstered its leadership with Matt Skelton's promotion to Chief Commercial Officer and new appointments of Jane Wright-Mitchell as Chief Legal Officer and Christopher Hite to the Board, signaling strengthened capabilities for commercialization. Despite elevated cash burn of $106.5 million in operating activities, the balance sheet remains robust with $596.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026, plus debt facility availability, positioned to fund operations beyond potential approval and launch. Key milestones include the July 7, 2026 PDUFA date for accelerated approval of atacicept, initial PIONEER trial results in Q2 2026, and ORIGIN 3 two-year eGFR data in Q1 2027, underscoring near-term catalysts for this BAFF/APRIL inhibitor in IgAN and other kidney diseases.